Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AG's gross profit for the
six
months ended in Dec. 2025 was CHF2,289 Mil. Sandoz Group AG's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was CHF4,250 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Sandoz Group AG's gross profit for the
six
months ended in Dec. 2025 was CHF2,289 Mil. Sandoz Group AG's Revenue for the
six
months ended in Dec. 2025 was CHF4,695 Mil. Therefore, Sandoz Group AG's Gross Margin % for the quarter that ended in Dec. 2025 was 48.76%.
Sandoz Group AG had a gross margin of 48.76% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 4 years, the highestGross Margin % of Sandoz Group AG was 47.44%. The lowest was 45.74%. And the median was 47.20%.
Sandoz Group AG (XSWX:SDZ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sandoz Group AG had a gross margin of 48.76% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Sandoz Group AG Gross Profit Related Terms
Sandoz Group AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SDZ vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF4,250 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sandoz Group AG (XSWX:SDZ) has a Gross Profit of CHF4,250 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Gross Profit too high?
Sandoz Group AG's current Gross Profit is CHF4,250 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Gross Profit compare to ZTS and UTHR?
Sandoz Group AG's Gross Profit of CHF4,250 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Gross Profit is CHF4,250 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Gross Profit of CHF4,250 Mil. The current Gross Profit is CHF4,250 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Gross Profit is CHF4,250 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score
Get the complete analysis for XSWX:SDZ
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
